OBN BioTuesday: 'A Spotlight on the Latest Research and Innovation In Cell & Gene Therapy'

We are pleased to announce details of our next BioTuesday on 21 February, supported by Venner Shipley and hosted by FTI Consulting, that will be spotlighting the:

'Latest Research and Innovation In Cell & Gene Therapy'

The Cell and Gene Therapy sectors are growing exponentially, with much progress being made both in and out of the lab. After many decades of work, the impact of cell and gene therapies continues to be significant, with a number of recent successes leading to approval of several life-saving treatments for patients.

During the evening, we will hear from some key thoughtleaders who will share a broad update on the latest research as well as a series of showcase presentations from some of the most exciting innovators in the cell & gene therapy space.

After the panel discussion, there will be the opportunity to network with guests over drinks and nibbles.


17.30 – 18.00 Delegate Registration & Networking

18.00 – 18.10 Welcome and Introductions by OBN and Venner Shipley

18.10 – 18.50 Keynote Presentation from:

  • Professor Amin Hajitou, Chair of Targeted Therapeutics, Imperial College London

18.50 – 19.40 Company showcase presentations from:

19.40 – 19.50 Audience Q&A

19.50 – 21.00 Networking Drinks Reception

21.00 - Event Close


FTI Consulting

200 Aldersgate
Aldersgate Street
London EC1A 4HD

United Kingdom

If you have any questions please contact

Contact Organizer

Show on map


OBN Member Complimentary Ticket
Member Price Complimentary
OBN Member Additional Ticket
Member Price £25
Non Member
Standard Price £50
Academic/Student/R&D Company
Standard Price Complimentary


  • Jason Foster (CEO of OriBiotech Ltd)

    Jason Foster

    CEO of OriBiotech Ltd

    Jason has held leading roles building consulting, pharma and technology companies over the last 20 years including Indivior PLC, which exited in a £2.5B listing (LSE: INDV) in December 2014.

    view more
  • Professor Amin Hajitou (Chair of Targeted Therapeutics at Imperial College)

    Professor Amin Hajitou

    Chair of Targeted Therapeutics at Imperial College

    view more
  • Remy Martin (Commercial Manager at eXmoor Pharma Concepts Ltd)

    Remy Martin

    Commercial Manager at eXmoor Pharma Concepts Ltd

    Remy is a skilled business development specialist, with experience gained both in commercial and research environments. This allows him to engage, discuss and understand clients’ needs in detail. He has an extensive knowledge of cell culture, advanced therapies, bioprocessing, process control and upstream process development which he utilises across a variety of interesting and innovative projects.

    view more
  • Mike McDonald (Founder & CEO of Maavrx Ltd)

    Mike McDonald

    Founder & CEO of Maavrx Ltd

  • Jeff Moore (Founder CEO of ATZ Therapeutics)

    Jeff Moore

    Founder CEO of ATZ Therapeutics

  • Vlad Seitan (Chief Scientific Officer at Laverock Therapeutics)

    Vlad Seitan

    Chief Scientific Officer at Laverock Therapeutics


    Former Group Leader at King’s College London, Department of Medical and Molecular Genetics. Extensive expertise in gene editing and RNAi technology research.

    view more